Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Pramlintide (compound)


PubChem Substance
Name: pramlintide
PubChem Substance ID: 10549634
Synonyms:
AC 0137; Symlin; Pramlintide Acetate; 187887-46-3; L-Lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-ysteinyl-L-alanyl-L-threonyl-L-lutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenyl-alanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylgly; 25-L-Proline-28-L-proline-29-L-prolineamylin (human) acetate (salt)
DrugBank
Identification
Name: pramlintide
Name (isomeric): DB01278
Drug Type: biotech
Synonyms:
Pramlintide acetate
Brand: Symlin, Symlin (Amylin Pharmaceuticals)
CAS number: 151126-32-8
Pharmacology
Indication: For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Pharmacology:
Pramlintide is a synthetic analog of amylin, a glucoregulatory hormone that is synthesized by pancreatic β-cells and released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. It is provided as an acetate salt. Pramlintide is a 37-amino acid polypeptide that differs ...
show more »
Mechanism of Action:
Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in ...
show more »
Absorption: The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%.
Protein binding: Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma).
Biotransformation: Metabolized primarily by the kidneys.
Route of elimination: Pramlintide is metabolized primarily by the kidneys.
Half Life: Approximately 48 minutes
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrimeprazineThe anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
TrospiumThe anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
ClidiniumPramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.
ThiothixeneThe anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
CarbinoxaminePramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur.
show more »

Targets